PBLS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

31.508

Open

29.450

VWAP

30.08

Vol

508.64K

Mkt Cap

3.69B

Low

28.390

Amount

15.30M

EV/EBITDA(TTM)

Total Shares

121.59M

EV/OCF(TTM)

P/S(TTM)

Parabilis Medicines, Inc., formerly FOG Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. It is built to develop transformative medicines addressing undruggable protein targets driving human disease. It leverages a proprietary platform to a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that reach conventional medicine. Its lead product candidate, zolucatetide, is the first and only investigational therapy that inhibits the b-catenin: TCF interaction, the critical downstream node of the Wnt/b-catenin pathway. Its preclinical pipeline provides Helicon approach and includes programs targeting two key drivers of prostate cancer, the ETS-related gene and the androgen receptor (AR) in its active state (ARON). Helicon discovery platform integrates advanced AI and physics-based computational modeling with peptide synthesis and experimental screening to discover and develop drug candidates.

Events Timeline

No data

News

6.0

07-06CNBC

Key Wall Street Rating Updates on Monday

8.5

06-28NASDAQ.COM

Parabilis IPO Outperforms SpaceX's Debut

8.5

06-28Fool

Parabilis Medicines IPO Surges 58%, Outpacing SpaceX

8.5

06-20Fool

Parabilis Medicines Director Increases Shareholding

8.5

06-20NASDAQ.COM

Parabilis Director's Share Purchase Signals Bullish Outlook

5.0

06-18NASDAQ.COM

Insider Buying Analysis: PBLS and ABTC

0 Analyst Rating

Wall Street analysts forecast PBLS stock price to rise

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

Leerink

Outperform

initiated

$40

AI Analysis

2026-07-06

New

Reason

Leerink

Price Target

$40

AI Analysis

2026-07-06

New

initiated

Outperform

Reason

Leerink initiated coverage of Parabilis Medicines with an Outperform rating and $40 price target. The firm believes the company's lead asset zolucatetide has the potential to be active across a number of Wnt-driven tumors, with over $10B in peak WW sales by 2045 in its forecasts. Continued derisking of zolucatetide and Parabilis' broader Helicon pipeline is expected to drive significant fundamental and strategic value, Leerink adds.

Evercore ISI

analyst

Outperform

initiated

$NULL

2026-07-06

New

Reason

Evercore ISI

analyst

Price Target

$NULL

2026-07-06

New

initiated

Outperform

Reason

Evercore ISI initiated coverage of Parabilis Medicines with an Outperform rating and no price target. Parabilis is \"taking bold strides in drug development,\" initial findings in desmoid tumors are \"promising,\" and the swift progression to Phase 3 \"highlights their commitment,\" the analyst tells investors. Beyond immediate indications, Parabilis is exploring orphan tumors like ACP and assessing larger cohorts, including hepatocellular carcinoma, the analyst added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PBLS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Parabilis Medicines Inc (PBLS.O) is 0.00, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Parabilis Medicines Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

Current PE

0.00

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

Current PS

0.00

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding PBLS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Parabilis Medicines Inc (PBLS) stock price today?

The current price of PBLS is 30.35 USD — it has increased 3.94

What is Parabilis Medicines Inc (PBLS)'s business?

What is the price predicton of PBLS Stock?

Wall Street analysts forecast PBLS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBLS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.